Please login to the form below

Not currently logged in
Email:
Password:

Former GSK CEO joins Synthego’s advisory board

Sir Andrew Witty will expand the team’s bioinformatics expertise

Andrew WittyGenome engineering solutions provider Synthego has appointed Sir Andrew Witty to its advisory board, a role that will see him work on biological research and grow its application development and bioinformatics expertise.

Witty has previously served on the board of directors at GlaxoSmithKline (GSK) while he was chief executive officer (CEO) from 2008 – 2017.

He said: “Synthego’s vision for automating biological research will revolutionise the industry by accelerating application development and enabling machine learning based insights.

“Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach.

“I look forward to contributing to the company’s success as the business extends further into the genome engineering market.”

Bringing more than 30 years’ experience to Synthego, Witty’s biopharma expertise ranges from product management and business development, to strategic partnerships.

Paul Dabrowski, CEO of Synthego, said: “Andrew’s broad experience in the biopharmaceutical space will help us unlock the full value of our platform and grow in key areas of the industry.

“This is part of the next step in bringing Synthego’s bioinformatics and experimental expertise to new applications and markets.

“Andrew’s appointment strengthens the company’s position as a leader in genome engineering solutions.”

22nd September 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics